Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Sarcoma is Scopus-indexed (Q2, CiteScore 4.3). Published by John Wiley and Sons Ltd.
Checked against the index lists dated .
ISSN 1357-714XVerify ISSN ↗1369-1643Verify ISSN ↗
Publisher: John Wiley and Sons Ltd
Cost to publish: About US$820 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Radiology, Nuclear Medicine and Imaging | 114 / 361 | 68th | Q2 |
| Oncology | 198 / 428 | 53rd | Q2 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1997–2024, best quartile Q2, CiteScore 4.3.
Sarcoma is Q2 in Radiology, Nuclear Medicine and Imaging (rank 114 of 361) and Q2 in Oncology (rank 198 of 428), by CiteScore 2025.
Sarcoma is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 4.3, quartile Q2, 68th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.560, quartile Q2, with an H-index of 57.
The publisher lists an article processing charge of about US$820 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Sarcoma is published by John Wiley and Sons Ltd. Its print ISSN is 1357-714X and its online ISSN is 1369-1643.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Sarcoma has an h-index of 65 and a 2-year mean of 4.56 citations per paper (OpenAlex). Its Scopus CiteScore is 4.3, quartile Q2. On 2-year citations it ranks #32 of 346 Scopus journals in Radiology, Nuclear Medicine and Imaging.
Sarcoma published 9 papers in 2024; its busiest recent year was 2020 with 56. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 53 research articles (2021–2024), authors are most often from United States (50.9%), Netherlands (6.8%) and Germany (6.2%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.